3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Genitourinary
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
18
Head and Neck Neoplasms
10
Melanoma
9
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Carcinoma, Transitional Cell
6
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Nasopharyngeal Carcinoma
4
Carcinoma, Merkel Cell
4
Thyroid Neoplasms
3
Sarcoma
3
Salivary Gland Neoplasms
3
Endometrial Neoplasms
3
Urinary Bladder Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma
2
Lymphoma
2
Liver Neoplasms
2
Histiocytoma, Malignant Fibrous
2
Esophageal Neoplasms
2
Interventions
Cisplatin
24
pembrolizumab
23
Magnetic Resonance Spectroscopy
19
Specimen Handling
16
Radiotherapy, Intensity-Modulated
12
Carboplatin
12
Cetuximab
11
1,2-diaminocyclohexaneplatinum II citrate
10
Platinum
9
Paclitaxel
9
Radiotherapy
6
Radiation
6
Fluorouracil
6
Biopsy
5
Taxes
4
Nivolumab
4
Docetaxel
4
(225)Ac-DOTA-c(RGDyK)
4
X-Rays
3
Pemetrexed
3
Fluorodeoxyglucose F18
3
reolysin
2
pralsetinib
2
ipatasertib
2
cemiplimab
2
atezolizumab
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Ipilimumab
×
Head & Neck
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts